PARKINSON DISEASE (Disorder)BI-POTATOSNCT07923513
Compulsive Eating and Brain's Reward System in Different Pathologies
A study testing MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy) in people with PARKINSON DISEASE (Disorder) and Bipolar 1 Disorder, run by University Hospital, Clermont-Ferrand at 1 site in France.
Trial summary
Compulsive eating behaviors represent a significant issue across various disorders such as Parkinson's disease, bipolar disorders, and obesity. Despite their apparent differences, these conditions share common underlying disturbances involving the brain's reward system, particularly within dopaminergic networks.6,7… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- PARKINSON DISEASE (Disorder), Bipolar 1 Disorder, Obesity (BMI>30)
- What is being tested?
- MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteFrance
- Study dates
- Dec 2026to Oct 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1-Common Criteria (Parkinson disease, Obesity, Bipolar patients)
- Men or women, right-handed, 18 to 80 years old
- With or without compulsive eating according to the QEWP-R
- No changes to long-term treatments in the previous month
- Cooperation and understanding to strictly comply with the conditions set out in the protocol
- Acceptance of the protocol and signing of a written informed consent
Show all 16Show fewer
- Affiliation to the social security system
- 2-Specific criteria Parkinsonian patients (n=25 with CE, n=25 without CE)
- Diagnosis of Parkinson's disease according to the Movement Disorders Society criteria
- BMI<30
- Obese patients (n=25 with CE, n=25 without CE)
- Obese patients according to HAS 2022 classification
- BMI≥30
- Bipolar patients (n=25 with CE, n=25 without CE)
- Diagnosis of bipolar disorder according to DSM 5 criteria
- BMI<30
Who cannot join
- 1-Common Criteria
- Dementia (MoCA <22)
- Severe depression (Beck Depression Inventory>30)
- Contraindications to MRI (implanted stimulator, insulin pump, intraocular metallic foreign bodies or close to the nervous and vascular systems, claustrophobia, non-removable dental appliance, tattoo on the face or neck, …)
- Refusal to be informed in case of incidental finding on MRI
- History of stroke or brain trauma that may impact MRI findings
Show all 25Show fewer
- Patients under guardianship, deprived of freedoms or protection of justice.
- Pregnant women, breastfeeding women
- 2- Specific criteria
- Parkinsonian patients:
- People suffering from neurological pathologies other than PD
- Patient suffering from psychiatric disorder
- Treated with deep brain stimulation
- Patients with severe tremor (> 3 for a tremor sub-item of the MDS-UPDRS III) or excessively severe dyskinesia contraindicating MRI
- Obese patients:
- Suffering from progressive neurological pathology and psychiatric disorder
- Weight >220kg contraindicating MRI
- Body (Shoulder) diameter > 220 cm contraindicating MRI
- History of bariatric surgery
- GLP1 treatment
- Bipolar patients:
- Suffering from neurological pathology and psychiatric disorder other than bipolar disorder
- Current acute depressive or hypomanic episode according to DSM 5
- Treated with deep brain stimulation or vagus nerve stimulation
- Electroconvulsivotherapy < 6 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
CHU de Clermont-Ferrand
Clermont-Ferrand, 63000
Lise Laclautre, promo_interne_drci@chu-clermontferrand.fr
About this study
Official title: Bipolar Disorders, Parkinson's Disease, ObesiTy and Compulsive eAting: TransnosOlogical Assessement of the Brain's Reward System
Compulsive eating behaviors represent a significant issue across various disorders such as Parkinson's disease, bipolar disorders, and obesity.
Despite their apparent differences, these conditions share common underlying disturbances involving the brain's reward system, particularly within dopaminergic networks.6,7 Previous neuroimaging studies have consistently reported reward system connectivity impairment associated with compulsive eating, in each of these disorders. However, few studies have simultaneously explored the neurobiological similarities and specificities of this common symptom, eating behavior, when occurring in different populations and disorders.
Read more
The Bi-POTATOS project proposes an original and innovative approach by adopting a transdiagnostic perspective, employing brain imaging and comprehensive psycho-behavioral assessments to investigate common behavioral characteristics and neural circuit alterations associated with compulsive eating across these three conditions. For the first time, this study will allow a direct comparison of the cerebral signatures linked to compulsive eating behavior, clearly distinguishing between transdiagnostic vulnerabilities and features unique to each clinical condition.
The central hypothesis is that similar dysfunctions in brain regions involved in motivation and impulsive decision-making underpin compulsive eating behaviors, irrespective of the initial diagnosis. However, the underlying pathology may modulate these mechanisms, introducing certain specificities.
By clarifying these common mechanisms, the Bi-POTATOS project will not only enhance our understanding of the neurobiological etiology of these disorders but also pave the way for innovative, targeted therapeutic interventions. This project will precisely identify whether specific neural alterations constitute a universally relevant therapeutic target, or conversely, determine which alterations necessitate tailored therapeutic strategies based on the underlying pathology.
- Being tested
- MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
- Keywords
- reward system, compulsive eating, brain functional signatures
- Medical subject headings
- Parkinson Disease, Obesity, Food Addiction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)Other
Also called Neuropsychological assessments, Dietitian
Neuropsychological assessment : motor impulsivity, motor inhibition, cognitive impulsivity (Stroop); decision making in an ambiguous context (Iowa Gambling Task), time perception (delay discounting reward task) and risk taking (Balloon analog Risk task).
MRI : The subjects will be scanned using a 3-Tesla MAGNETOM Vida scanner (Siemens, Erlangen, Germany) with a 64 channel head coil Dietician : 3 days food record
| Study group | Role | What they receive |
|---|---|---|
| Study Group | Experimental | Visit 1 : selection visit
* Inform consent and participation agreement
* Assessment of the disease and eating behavior disorder severity, medication taken, as well as a standard medical examination (measurement of weight, height and blood pressure) Cognitive function, impulsive trait of personality, depression, anxiety, restless legs syndrome, REM sleep behavior disorder and pain will be assessed.
Visit 2 : investigational visit
* MRI scan
* neuropsychological assessments Receives: Other: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of resting state seed-based functional connectivity from the limbic striatum (seed: ventral striatum) by MRI.
MRI is a 3-Tesla MAGNETOM Vida scanner (Siemens, Erlangen, Germany) with a 64 channel head coil.
The subjects were asked to hold still, with their eyes open and not to think of anything particular. Foam padding was employed to reduce head movement and earplugs were used to reduce scanner noise.
The high resolution anatomical images were obtained through a T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) sequence with the following parameters: repetition time (TR): 2300 ms, echo time (TE): 3.08 ms, inversion time (IT): 900 ms, flip angle (FA): 9°, matrix: 288 x 288, 176 slices, slice thickness: 1mm.
Resting-state functional MRI images were obtained using an EPI sequence with the following parameters: TR: 3000ms, TE: 30ms, FA: 81°, field of view (FOV): 192 mm, 55 slices, slice thickness: 3.3 mm, gap between slices: 3.3 mm, pixel bandwidth: 2441 Hz/Pixel, number of time points: 180, acquisition duration: 9 minutes).
Measured: At visit 2, between 1 and 12 weeks after patient enrollment
Secondary outcomes (23)
Demographical data
sex
Measured: at visit 1, selection visit - Day 0
Demographical data
Age (year)
Measured: at visit 1, selection visit - Day 0
Demographical data
weight (kg)
Measured: at visit 1, selection visit - Day 0
Demographical data
size (m)
Measured: at visit 1, selection visit - Day 0
Parkinson Disease severity
Assessment of parkinson desease with the MDS-UPDRS (Movement Disorders Society - Unified Parkinson's Disease Rating Scale ) scale, completed by the investigator.
Measured: at visit 1, selection visit - Day 0
Bipolar Disease severity
Assessment of bipolar desease with MADRS (Montgomery-Asberg Depression Rating Scale) and YMRS (Young Mania Rating Scale) scale, completed by the investigator.
Measured: at visit 1, selection visit - Day 0
Obesity disease severity
Obesity classification according to Health French Agency (Haute Autorité de Santé) 2022, completed by the investigator.
Measured: at visit 1, selection visit - Day 0
Impulsive trait of Personality according the Barratt impulsiveness scale (BIS-11)
This self questionnaire is completed by the patient during the selection visit
Measured: at visit 1, selection visit - Day 0
Eating behavior disorder severity
Self reported eating behavior disorder using 3 questionnaires (QEWP5 (Questionnaire on Eating and Weight Patterns5), DEBQ (Dutch Eating Behaviour Questionnaire) and food craving questionnaire))
Measured: at visit 1, selection visit - Day 0
Presence of Anxiety and/or depression according the Beck depression and anxiety scale
These self questionnaires is completed by the patient during the selection visit
Measured: at visit 1, selection visit - Day 0
Presence of restless legs syndrome according the International Restless Legs Syndrome (Rating Scale)
This questionnaire is completed by the investigator during the selection visit
Measured: at visit 1, selection visit - Day 0
Intensity and Pain caracteristics
Patients will evaluate their pain using 2 self questionnaires (3-PDQ, BPI (Brief Pain Inventory))
Measured: at visit 1, selection visit - Day 0
Impulsive compulsive behaviors rating scale for PD (QUIP-RS)
The QUIP-RS is a brief 28-item patient-reported or clinician-rated scale developped for measure of severity of ICDs. Each item is rated on a 5-point Likert scale assessing frequency of symptoms with a range of scores from 0 (never) to 4 (very often).
Measured: at visit 2, between 1 and 12 weeks after selection visit
Spontaneous food intake
Patients will report thier spontaneous food intake for 3 days using a dietary data collected. Patient nutritional intakes will be analysed using Nutrilog software
Measured: at visit 2, between 1 and 12 weeks after selection visit
Motor impulsivity (Go/No Go task)
Motor impulsivity will be assessed with the Go/No-go task. It is a simple experimental paradigm that requires participants to respond as quickly as possible (Go) to a particular class of stimuli, for example by pressing a key on a keyboard, and not to respond to other classes of stimuli (No Go). The key behaviour measured with this experiment is the participants' ability to withhold a response on No-go trials.
Measured: at visit 2, between 1 and 12 weeks after selection visit
Motor inhibition (Stop Signal Task (SST))
The Stop Signal Task (SST) is a test that measures motor inhibition. The participant must respond quickly to Go stimuli but interrupt their response when a stop signal appears. The key index, the Stop Signal Reaction Time (SSRT), reflects the time required to stop an ongoing action. This test will be performed by neuropsychologist.
Measured: at visit 2, between 1 and 12 weeks after selection visit
Iowa Gambling Task (IGT)
IGT assesses risk-based learning by relying on a system of rewards and punishments within a simulated context of uncertainty, representing a real-life decision-making situation.
Participants choose cards from four decks, each associated with varying amounts of monetary gains and losses. Over time, advantageous decks yield higher net rewards, while disadvantageous decks lead to net losses.
Performance on the task reflects an individual's capacity to balance immediate rewards against long-term outcomes, thereby providing insight into adaptive decision-making and risk evaluation processes.
This test will be performed by neuropsychologist.
Measured: at visit 2, between 1 and 12 weeks after selection visit.
Cognitive impulsivity (Stroop)
The Stroop Test is a cognitive task designed to evaluate attentional control and the ability to inhibit automatic responses when faced with conflicting information. Participants are asked to name the color of the ink in which words are printed, even when the word itself refers to a different color (e.g., GREEN printed in red ink). This requires suppressing the automatic tendency to read the word and instead focusing on the ink color. The difference in performance between congruent and incongruent conditions, known as the Stroop interference effect, is a key indicator of cognitive inhibition and executive control. This test will be performed by neuropsychologist.
Measured: at visit 2, between 1 and 12 weeks after selection visit
Time perception (delay discounting reward task)
Participants make choices between two alternatives: a larger reward available after a delay (across seven delay intervals) and a smaller reward available immediately. The value of the immediate reward is systematically adjusted, either increasing or decreasing, in separate blocks. The task assesses preferences for immediate versus delayed gratification using two reward types: money and food. This test will be performed by neuropsychologist.
Measured: at visit 2, between 1 and 12 weeks after selection visit
Balloon analog Risk task
Participants are given 30 balloons (by default). For each balloon, they can choose either to inflate it further or to collect their earnings. With each successful inflation, they can earn money. However, if a balloon bursts before the participant collects the potential earnings, they lose all potential gains associated with that balloon.
The average number of pumps on balloons that do not burst is the primary dependent variable in this paradigm. A higher number of pumps reflects increased risk-taking behavior. This test will be performed by neuropsychologist.
Measured: at visit 2, between 1 and 12 weeks after selection visit
Surface based (Freesurfer) and Voxel based (SPM) morphometry performed by MRI
MRI is a 3-Tesla MAGNETOM Vida scanner (Siemens, Erlangen, Germany) with a 64 channel head coil.
The subjects were asked to hold still, with their eyes open and not to think of anything particular. Foam padding was employed to reduce head movement and earplugs were used to reduce scanner noise.
The high resolution anatomical images were obtained through a T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) sequence with the following parameters: repetition time (TR): 2300 ms, echo time (TE): 3.08 ms, inversion time (IT): 900 ms, flip angle (FA): 9°, matrix: 288 x 288, 176 slices, slice thickness: 1mm.
Resting-state functional MRI images were obtained using an EPI sequence with the following parameters: TR: 3000ms, TE: 30ms, FA: 81°, field of view (FOV): 192 mm, 55 slices, slice thickness: 3.3 mm, gap between slices: 3.3 mm, pixel bandwidth: 2441 Hz/Pixel, number of time points: 180, acquisition duration: 9 minutes).
Measured: at visit 2, between 1 and 12 weeks after selection visit
Structural connectivity (MRtrix and TRACTseg) performed by MRI
MRI is a 3-Tesla MAGNETOM Vida scanner (Siemens, Erlangen, Germany) with a 64 channel head coil.
The subjects were asked to hold still, with their eyes open and not to think of anything particular. Foam padding was employed to reduce head movement and earplugs were used to reduce scanner noise.
The high resolution anatomical images were obtained through a T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) sequence with the following parameters: repetition time (TR): 2300 ms, echo time (TE): 3.08 ms, inversion time (IT): 900 ms, flip angle (FA): 9°, matrix: 288 x 288, 176 slices, slice thickness: 1mm.
Resting-state functional MRI images were obtained using an EPI sequence with the following parameters: TR: 3000ms, TE: 30ms, FA: 81°, field of view (FOV): 192 mm, 55 slices, slice thickness: 3.3 mm, gap between slices: 3.3 mm, pixel bandwidth: 2441 Hz/Pixel, number of time points: 180, acquisition duration: 9 minutes).
Measured: at visit 2, between 1 and 12 weeks after selection visit
Resting state seed-based functional connectivity from the limbic striatum performed by MRI
MRI is a 3-Tesla MAGNETOM Vida scanner (Siemens, Erlangen, Germany) with a 64 channel head coil.
The subjects were asked to hold still, with their eyes open and not to think of anything particular. Foam padding was employed to reduce head movement and earplugs were used to reduce scanner noise.
The high resolution anatomical images were obtained through a T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) sequence with the following parameters: repetition time (TR): 2300 ms, echo time (TE): 3.08 ms, inversion time (IT): 900 ms, flip angle (FA): 9°, matrix: 288 x 288, 176 slices, slice thickness: 1mm.
Resting-state functional MRI images were obtained using an EPI sequence with the following parameters: TR: 3000ms, TE: 30ms, FA: 81°, field of view (FOV): 192 mm, 55 slices, slice thickness: 3.3 mm, gap between slices: 3.3 mm, pixel bandwidth: 2441 Hz/Pixel, number of time points: 180, acquisition duration: 9 minutes).
Measured: at visit 2, between 1 and 12 weeks after selection visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study startDec 2026 (estimated)
- Primary completionJul 2029 (estimated)
- Study completionOct 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PARKINSON DISEASE (Disorder)Studies of the same condition, open and under way.
- More trials run by University Hospital, Clermont-FerrandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07923513
- Sponsor's protocol ID
- AOI 2025 MARQUES
- Other IDs
- 2026-A00850-51
- Acronym
- BI-POTATOS
- Status last verified
- Nov 2026
- First submitted
- 27 Jul 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bipolar Disorders, Parkinson's Disease, ObesiTy and Compulsive eAting: TransnosOlogical Assessement of the Brain's Reward System
- ClinicalTrials.gov ID
- NCT07923513
- Acronym / sponsor ID
- BI-POTATOS / AOI 2025 MARQUES
- Keywords
- reward system, compulsive eating, brain functional signatures
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- University Hospital, Clermont-FerrandUniversity, hospital or other
- Study start
- Dec 2026 (estimated)
- Primary completion
- Jul 2029 (estimated)
- Study completion
- Oct 2029 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Compulsive eating behaviors represent a significant issue across various disorders such as Parkinson's disease, bipolar disorders, and obesity.
Despite their apparent differences, these conditions share common underlying disturbances involving the brain's reward system, particularly within dopaminergic networks.6,7 Previous neuroimaging studies have consistently reported reward system connectivity impairment associated with compulsive eating, in each of these disorders. However, few studies have simultaneously explored the neurobiological similarities and specificities of this common symptom, eating behavior, when occurring in different populations and disorders.
The Bi-POTATOS project proposes an original and innovative approach by adopting a transdiagnostic perspective, employing brain imaging and comprehensive psycho-behavioral assessments to investigate common behavioral characteristics and neural circuit alterations associated with compulsive eating across these three conditions. For the first time, this study will allow a direct comparison of the cerebral signatures linked to compulsive eating behavior, clearly distinguishing between transdiagnostic vulnerabilities and features unique to each clinical condition.
The central hypothesis is that similar dysfunctions in brain regions involved in motivation and impulsive decision-making underpin compulsive eating behaviors, irrespective of the initial diagnosis. However, the underlying pathology may modulate these mechanisms, introducing certain specificities.
By clarifying these common mechanisms, the Bi-POTATOS project will not only enhance our understanding of the neurobiological etiology of these disorders but also pave the way for innovative, targeted therapeutic interventions. This project will precisely identify whether specific neural alterations constitute a universally relevant therapeutic target, or conversely, determine which alterations necessitate tailored therapeutic strategies based on the underlying pathology.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study Group | Experimental | Other: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)Visit 1 : selection visit * Inform consent and participation agreement * Assessment of the disease and eating behavior disorder severity, medication taken, as well as a standard medical examination (measurement of weight, height and blood pressure) Cognitive function, impulsive trait of personality, depression, anxiety, restless legs syndrome, REM sleep behavior disorder and pain will be assessed. Visit 2 : investigational visit * MRI scan * neuropsychological assessments |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- 1-Common Criteria (Parkinson disease, Obesity, Bipolar patients)
- Men or women, right-handed, 18 to 80 years old
- With or without compulsive eating according to the QEWP-R
- No changes to long-term treatments in the previous month
- Cooperation and understanding to strictly comply with the conditions set out in the protocol
Key exclusion criteria (25 listed)
- 1-Common Criteria
- Dementia (MoCA <22)
- Severe depression (Beck Depression Inventory>30)
- Contraindications to MRI (implanted stimulator, insulin pump, intraocular metallic foreign bodies or close to the nervous and vascular systems, claustrophobia, non-removable dental appliance, tattoo on the face or neck, …)
- Refusal to be informed in case of incidental finding on MRI
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)Also: Neuropsychological assessments, DietitianNeuropsychological assessment : motor impulsivity, motor inhibition, cognitive impulsivity (Stroop); decision making in an ambiguous context (Iowa Gambling Task), time perception (delay discounting reward task) and risk taking (Balloon analog Risk task). MRI : The subjects will be scanned using a 3-Tesla MAGNETOM Vida scanner (Siemens, Erlangen, Germany) with a 64 channel head coil Dietician : 3 days food record | Other | Study Group |
Primary outcome
Assessment of resting state seed-based functional connectivity from the limbic striatum (seed: ventral striatum) by MRI.
Time frame: At visit 2, between 1 and 12 weeks after patient enrollment
MRI is a 3-Tesla MAGNETOM Vida scanner (Siemens, Erlangen, Germany) with a 64 channel head coil. The subjects were asked to hold still, with their eyes open and not to think of anything particular. Foam padding was employed to reduce head movement and earplugs were used to reduce scanner noise. The high resolution anatomical images were obtained through a T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) sequence with the following parameters: repetition time (TR): 2300 ms, echo time (TE): 3.08 ms, inversion time (IT): 900 ms, flip angle (FA): 9°, matrix: 288 x 288, 176 slices, slice thickness: 1mm. Resting-state functional MRI images were obtained using an EPI sequence with the following parameters: TR: 3000ms, TE: 30ms, FA: 81°, field of view (FOV): 192 mm, 55 slices, slice thickness: 3.3 mm, gap between slices: 3.3 mm, pixel bandwidth: 2441 Hz/Pixel, number of time points: 180, acquisition duration: 9 minutes).
23 secondary outcomes
Demographical data
Time frame: at visit 1, selection visit - Day 0
Demographical data
Time frame: at visit 1, selection visit - Day 0
Demographical data
Time frame: at visit 1, selection visit - Day 0
Demographical data
Time frame: at visit 1, selection visit - Day 0
Parkinson Disease severity
Time frame: at visit 1, selection visit - Day 0
Bipolar Disease severity
Time frame: at visit 1, selection visit - Day 0
Obesity disease severity
Time frame: at visit 1, selection visit - Day 0
Impulsive trait of Personality according the Barratt impulsiveness scale (BIS-11)
Time frame: at visit 1, selection visit - Day 0
Eating behavior disorder severity
Time frame: at visit 1, selection visit - Day 0
Presence of Anxiety and/or depression according the Beck depression and anxiety scale
Time frame: at visit 1, selection visit - Day 0
Presence of restless legs syndrome according the International Restless Legs Syndrome (Rating Scale)
Time frame: at visit 1, selection visit - Day 0
Intensity and Pain caracteristics
Time frame: at visit 1, selection visit - Day 0
Impulsive compulsive behaviors rating scale for PD (QUIP-RS)
Time frame: at visit 2, between 1 and 12 weeks after selection visit
Spontaneous food intake
Time frame: at visit 2, between 1 and 12 weeks after selection visit
Motor impulsivity (Go/No Go task)
Time frame: at visit 2, between 1 and 12 weeks after selection visit
Motor inhibition (Stop Signal Task (SST))
Time frame: at visit 2, between 1 and 12 weeks after selection visit
Iowa Gambling Task (IGT)
Time frame: at visit 2, between 1 and 12 weeks after selection visit.
Cognitive impulsivity (Stroop)
Time frame: at visit 2, between 1 and 12 weeks after selection visit
Time perception (delay discounting reward task)
Time frame: at visit 2, between 1 and 12 weeks after selection visit
Balloon analog Risk task
Time frame: at visit 2, between 1 and 12 weeks after selection visit
Surface based (Freesurfer) and Voxel based (SPM) morphometry performed by MRI
Time frame: at visit 2, between 1 and 12 weeks after selection visit
Structural connectivity (MRtrix and TRACTseg) performed by MRI
Time frame: at visit 2, between 1 and 12 weeks after selection visit
Resting state seed-based functional connectivity from the limbic striatum performed by MRI
Time frame: at visit 2, between 1 and 12 weeks after selection visit
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
Related trials for PARKINSON DISEASE (Disorder)
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy) in people with PARKINSON DISEASE (Disorder) and Bipolar 1 Disorder, run by University Hospital, Clermont-Ferrand at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lise Laclautre (+33473754963, promo_interne_drci@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of resting state seed-based functional connectivity from the limbic striatum (seed: ventral striatum) by MRI. (time frame: At visit 2, between 1 and 12 weeks after patient enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.